Nearly half the world’s adults will experience lower urinary tract symptoms by 2018

Study provides detailed projections for North and South America, Africa, Asia and Europe

 

(September 27, 2011) – Nearly half of all adults over 20 will experience at least one lower urinary tract symptom by 2018 – an estimated 2.3 billion people and a worldwide increase of 18% in just one decade – according to research in the October issue of the urology journal BJUI.

 

Other issues like incontinence will also increase, with South America, Asia and the developing regions of Africa particularly affected by the conditions, which are more common as people get older.

 

"Our study suggests that urinary and bladder symptoms are already highly prevalent worldwide and that these rates will increase significantly as the population ages" says lead author Dr Debra E Irwin from the Department of Epidemiology at the University of North Carolina, USA.

 

"These findings raise a number of important worldwide issues that will need to be tackled, as a matter of urgency, by clinicians and public health experts if we are to prevent, and manage, these conditions."

 

The research team calculated the numbers and prevalence of individuals aged 20 years plus affected by each condition in 2008, using data on gender and age from two key sources:

 

  • Worldwide and regional population estimates from the US Census Bureau International Data Base
  • The EPIC study, a large population-based, cross-sectional telephone survey of more than 19,000 men and women in five countries, led by Dr Irwin.

 

The data was then extrapolated to provide 2013 and 2018 estimates for lower urinary tract symptoms (LUTS), overactive bladder (OAB), urinary incontinence (UI) and LUTS suggestive of bladder outlet obstruction (LUTS/BOO), using the current symptom definitions from the International Continence Society.

 

"It is well known that people do not always seek medical attention for urinary problems, so basing our figures on studies using self-reported symptoms is an effective way of measuring worldwide prevalence" explains Dr Irwin.

 

Key findings of the analysis include:

 

  • The worldwide prevalence of LUTS will increase to just under 46% by 2018, affecting 47% of women and 45% of men.
  • Between 2008 and 2018 the number of people experiencing at least one LUTS will have grown by 18%, affecting an estimated 2.3 billion people, with the biggest increase in Africa (30%), followed by South America (20.5%), Asia (20%), North America (16%) and Europe (2.5%).
  • OAB will have increased by 20% between 2008 and 2018, affecting an estimated 546 million people, with the biggest increase in Africa (31%), followed by South America (22%), Asia (22%), North America (18%) and Europe (4%).
  • UI will have increased by 22% between 2008 and 2018, affecting an estimated 423 million people, with the biggest increase in Africa (31%), followed by South America (25%), Asia (24%), North America (18%) and Europe (5%).
  • LUTS/BOO will have increased by 18.5% between 2008 and 2018, affecting an estimated 1.1 billion people, with the biggest increase in Africa (30%), followed by South America (21%), Asia (20%) North America (16%) and Europe (3%).

 

"We believe that our study underlines the clear and urgent need to improve the awareness, prevention, diagnosis and management of these conditions" says Dr Irwin, who worked with co-authors from the USA, UK and Sweden.

 

"International and national programmes that increase public awareness, educate clinicians and implement public health campaigns that tackle the social stigma of LUTS, will be a significant step towards reaching this objective.

 

"These public health programmes would need to be adapted by region, because countries often differ in their healthcare resources, treatment guidelines and social perceptions."

 

 

The full paper on the study, which was funded by Pfizer, provides detailed breakdowns of individuals with LUTS by gender and year. It also provides further statistics on the increases expected by 2013.

 

 

Notes to editors

 

Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary. Irwin et al. BJUI. 108, pp1132. (October 2011) doi:10.1111/j.1464-410X.2010.09993,10498.x

 

Established in 1929, BJUI is edited by Professor John Fitzpatrick from Mater Misericordiae University Hospital and University College Dublin, Ireland. It provides its international readership with invaluable practical information on all aspects of urology, including original and investigative articles and illustrated surgery. http://wileyonlinelibrary.com/journal/BJU

 

 


British Journal of Urology International (BJUI), 27.09.2011 (tB).

MEDICAL NEWS

New guidance to prevent the tragedy of unrecognized esophageal intubation
Overly restrictive salt intake may worsen outcomes for common form…
COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Scientists discover how salt in tumours could help diagnose and…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Kaltplasma bei diabetischem Fußsyndrom wirkt via Wachstumsfaktoren
Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…

ERNÄHRUNG

Gesunde Ernährung: „Nicht das Salz und nicht das Fett verteufeln“
Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?

ONKOLOGIE

Nahrungsergänzungsmittel während der Krebstherapie: Es braucht mehr Bewusstsein für mögliche…
Fusobakterien und Krebs
Fortgeschrittenes Zervixkarzinom: Pembrolizumab verlängert Leben
Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
Aktuelle Kongressdaten zum metastasierten Mammakarzinom und kolorektalen Karzinom sowie Neues…

MULTIPLE SKLEROSE

Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…